AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04563052 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Program on Air Pollution as a Health Risk Reduction Strategy
Description: A power point presentation about the health impact of exposure to fine particulate matter (PM2.5) on health. Pm2.5 is found outdoors and indoors. Information will be reviewed about steps to take for the participants to locate the information using a smart phone and steps to take to decrease exposure to prevent illness such as heart disease or strokes.
Study NCT03766594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil Citrate
Description: Respatio(R) 25mg tablets four times daily for 24 days preconceptionally starting first day of previous period
Study NCT03766594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Folic acid(R) 0.5mg tablets once daily for 3 months preconceptionally
Study NCT00857558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saxagliptin
Description: orally administration at 2.5 mg once a day for 12 weeks
Study NCT00857558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saxagliptin
Description: orally administration at 5 mg once a day for 12 weeks
Study NCT00857558 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: orally administration once a day for 12 weeks
Study NCT03766594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablet apparently identical to Respatio(R) 25mg tablets, taken four times daily for 24 days preconceptionally starting first day of previous period
Study NCT01246453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrapleurally Alteplase vs Intrapleurally Urokinase
Description: Alteplase 10 mg and urokinase 100000 intrapleurally administered, once daily for three days and if necessary 6 days
Study NCT01875107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin pre-treatment
Description: insulin pre-treatment of pregnant diabetic patients who receive betamethasone
Study NCT02684786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reserpine
Description: Patients with qualifying hemodynamics from prior right heart catheterization will receive open label reserpine, 0.05 mg by mouth daily for two weeks, then 0.10 mg by mouth daily for two weeks, and then have repeat non-invasive assessments of status
Study NCT02684786 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stellate ganglion block
Description: Patients with suspected group 2 pulmonary hypertension by clinical and non-invasive assessments and are scheduled to undergo clinically indicated right heart catheterization will have pulmonary artery pressures measured. If qualifying severity of group 2 pulmonary hypertension is present, after clinically indicated assessment of inhaled nitric oxide, their baseline hemodynamics will be allowed to re-equilibrate over 10 minutes, and then ultrasound guided left stellate ganglion block with lidocaine will be performed, and hemodynamics reassessed 10 minutes afterward
Study NCT02684786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: Patients with suspected group 2 pulmonary hypertension by clinical and non-invasive assessments and are scheduled to undergo clinically indicated right heart catheterization will have pulmonary artery pressures measured. If qualifying severity of group 2 pulmonary hypertension is present, after clinically indicated assessment of inhaled nitric oxide, their baseline hemodynamics will be allowed to re-equilibrate over 10 minutes, and then ultrasound guided left stellate ganglion block with lidocaine will be performed, and hemodynamics reassessed 10 minutes afterward
Study NCT02323581 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular treatment of Thoracoabdominal Aortic Aneurysm
Description: A TAAA is an abnormal enlargement (ballooning out) of the main artery (the aorta) and involves all or part of the aorta in your chest as well as all or part of the aorta in the abdomen. It also involves the part of the aorta where the arteries that bring blood to the liver, stomach and intestines and kidneys are attached.~This investigational procedure that is being studied uses stent-grafts (cylindrical fabric tubes (grafts), with metal springs (stents) attached). The stent-grafts are placed inside the aneurysmal (weakened) area of the aorta to re-line it. These customized stent-grafts have special branches attached to them or openings (called fenestrations) that are used to keep blood flowing to the arteries that supply the liver, stomach, intestines and kidneys. The investigational stent graft will be designed and custom-made specifically for your aneurysm.
Study NCT02669719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: chemotherapy followed dendritic cells
Description: Pemetrexed and carboplatin would be administered on day 1 of each 3-week cycle.Patients will start with dendritic cells treatment on Day 15 of pemetrexed and carboplatin chemotherapy from Cycle 3 provided that both leukapheresis and the production of dendritic cells are successful.
Study NCT02669719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed and carboplatin
Description: Chemotherapy with 4-6 cycles of pemetrexed and carboplatin as first-line induction chemotherapy followed by pemetrexed as maintenance therapy.
Study NCT02729792 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: intermittent theta burst stimulation (iTBS)
Study NCT02323581 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular treatment of Aortic Arch Aneurysms
Description: An aortic arch aneurysm is an abnormal enlargement (ballooning out) of the main artery (the aorta). The ascending aorta and aortic arch is the first part of the vessel as it exits the heart and makes a turn around the area of the collar bone. This part of the aorta gives branches that supply the head, brain and arms.~The arch branch endovascular graft includes the main aortic arch portion and one to three cuffs (side branches) that allow the graft to be located in the aortic arch. The number of cuffs is decided based on the anatomy of your aneurysm. The arteries in the aortic arch are the innominate artery (Zone 0), left common carotid artery (Zone 1) and the left subclavian artery (Zone 2). These arteries supply the right arm and right side of the brain, the left side of the brain and the left arm, respectively.
Study NCT03086941 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-gel
Description: To compare between use of I-gel as a conduit for blind intubation and as a conduit for fiberoptic guided intubation in children. We also aim to validate the use of I-gel as conduit for blind intubation in absence of fiberoptic or lack of experience of its use.
Study NCT02729792 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: intermittent theta burst stimulation (iTBS)
Study NCT00408161 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management
Description: prize contingency management (CM) -- 6-month treatment plus standard case management treatment and follow-ups at 9, 12, and 18 months after intake
Study NCT00408161 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard case management treatment
Description: 6-month treatment standard case management treatment, and follow-ups scheduled at 9, 12, and 18 months after intake.
Study NCT04789200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX9 Oral Contrast Agent
Description: Distension and marking of the bowel lumen will be compared between the 1st and 2nd scan. Ability to see IV contrast enhancement will be assessed on the 3rd scan in relationship to the 2nd scan.
Study NCT01938417 — intervention group
Intervention type: DRUG
Intervention: tobramycin
Study NCT04094909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rh-endostatin
Description: Squamous NSCLC: Rh-endostatin+Pembrolizumab+carboplatin or cisplatin +\[nab\]-paclitaxel during the treatment. Rh-endostatin+Pembrolizumab during the maintenance period.~Non-squamous NSCLC: Rh-endostatin+Pembrolizumab+carboplatin or cisplatin +pemetrexed during the treatment. Rh-endostatin+Pembrolizumab + pemetrexed during the maintenance period.
Study NCT00701311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-10004
Description: CC-10004 20 mg per day
Study NCT05002361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 24 mg intravenous Dexamethasone (6 ml)
Study NCT05002361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: 6 ml of isotonic saline
Study NCT03902340 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiTENS
Description: ActiTENS is a rechargeable box, weighing 64g attached by Velcro to an adhesive support, which can be positioned on the skin at any position chosen by the patient. The patient will use the programme (P4) prescribed by his doctor and will regulate the intensity of stimulation using an application downloaded to his smartphone which will communicate with the box via Bluetooth.
Study NCT03902340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Level 2 Analgesic Treatments
Description: There are 4 level 2 oral analgesic treatments indicated for chronic nociceptive pain of moderate to severe intensity (between 4 and 7 on a simple numerical scale of 11 points) (12):~* Tramadol immediate release formulation (IR, one intake every 6 hours) or prolonged release formulation (PR, one intake every 12 hours); maximum posology 400mg/24h.~* Dihydrocodeine: 60mg every 12 hours; maximum posology 120mg/24h.~* Combination of paracetamol and codeine in a fixed combination every 6 hours; maximum posology of codeine: 300mg/24h.~* Combination of paracetamol and tramadol in a fixed combination; maximum posology of tramadol: 8 tablets/24h ie 300mg/24h.
Study NCT03965117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: norepinephrine will be started at 0,1 mcg/kg/min and titrated according to its haemodynamic effect. After baseline MAP (which is > 60 mmHg), norepinephrine is targeted according baseline MAP. At T2, MAP is between 10 - 20 % above baseline (T1), at T3 MAP is between 20 - 30 % above baseline (T1).
Study NCT01924234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Study NCT01924234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Study NCT03059992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrexafungerp
Description: Experimental Study Drug
Study NCT02449044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Once Daily
Study NCT04323735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Culturelle 10 Billion CFU Capsule
Description: LGG® (Culturelle Probiotic with Lactobacillus RhamnosusGG, shown to produce the largest amount of antibacterial substances against pathogenic bacteria) will be used. For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the indwelling catheter (the catheter will not be changed as this would represent 2 interventions). Participants will be instructed the plug their catheter for 1 hour. Participants will receive 2 or 4 LGG capsules (depending on randomization group) and will repeat this process the following day (Low dose) or twice daily for a total of four doses (High dose) according to randomization group.
Study NCT06697613 — intervention group
Intervention type: PROCEDURE
Intervention: Hyperthermic intraperitoneal chemotherapy
Description: Patients diagnosed with FIGO Stage 3 or stage 4 ovarian cancer received hyperthermic intraperitoneal chemotherapy with cisplatin following cytoreductive surgery including primary debulking surgery, interval debulking surgery and secondary debulking surgery.
Study NCT02608086 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychoeducation
Description: Participants in Control Group will be delivered a flyer named What can I do facing a crisis?, containing information about normal reactions to crisis, what to do to return to normal life and which are the signals of an initial trauma.
Study NCT02608086 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological First Aid
Description: Psychology students (PFA Providers) will intervene according to an adapted protocol based on the WHO PFA Operation Guide 2012. Protocol for this study contemplates 4 steps: 1. Active Listening 2. Relaxing and Breathing Techniques 3. Help in prioritizing needs 4. Help in contacting network and services. Moreover, participants in this group will receive a brochure with full contact information of public network, and a flyer named What can I do facing a crisis?.
Study NCT04928131 — intervention group
Intervention type: OTHER
Intervention: No intervention - retrospective observational cohort study
Study NCT04254250 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Preoperative risk estimation of disc herniation recurrence
Description: Risk estimation of disc herniation recurrence will be evaluated preoperatively, depend on the risk significance each patient will be assigned to one of two groups - with high risk and low risk. Then each patient will undergo conventional one-level microdiscectomy.
Study NCT01994005 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facebook
Description: Facebook page with contraception information used for counseling
Study NCT01994005 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Pamphlet
Description: Contraceptive knowledge pamphlets
Study NCT02124980 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Line
Study NCT02981160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary
Description: The REE testing will be done with the Breezing device, a breath analyzer developed at Arizona State University. The Breezing device is an indirect calorimetry analyzer that measures the rate of oxygen consumption and carbon dioxide production, and determines how much energy the body is burning (REE), and the type of nutrients the body uses to produce energy (energy source). The Breezing device is a cellphone-size, battery-operated, portable technology that syncs with smartphones and electronic pads. The patients will be asked to breathe into a mouthpiece connected to the Breezing device; the data will be then beamed wirelessly to the device. The breath analysis data will displayed on the screen in conjunction with an estimate of total calories burned each day (total energy expenditure, TEE).
Study NCT03074448 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aquanet
Description: Aquanet bowel cleansing devices
Study NCT01461616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPH
Description: equal doses of NPH insulin, insulin Detemir and insulin glargine injection
Study NCT01461616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Detemir
Description: equal doses of NPH insulin, insulin Detemir and insulin glargine injection
Study NCT01461616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine
Description: equal doses of NPH insulin, insulin Detemir and insulin glargine injection
Study NCT01316497 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Description: RIPC was performed by applying a blood pressure cuff around the child's leg. The cuff was inflated to 40 mmHg above the systolic pressure in 4 cycles of 5 minutes. Every cycle of ischemia was followed by 5 minutes of reperfusion. The first RIPC cycle started after anesthesia induction when invasive arterial blood pressure was monitored. Appropriate cuff size was used choosing between four sizes. For reproducibility RIPC was performed on the right leg with only a few exceptions, when the leg was used for invasive catheters.
Study NCT01316497 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The cuff was applied on the leg without inflation in the control group.
Study NCT04660968 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic health behaviour change intervention
Description: The dyadic behaviour change intervention adopts a dyadic coping perspective wherein appraisal of shared responsibility, agreement on tasks, and collaboration are fostered throughout the intervention. The intervention will target four behaviour goals: reducing overall caloric intake, substituting empty calorie foods with healthier alternatives, reducing sedentary behaviour, and increasing physical activity. The specific behavioural change strategies will include motivational interviewing, self-monitoring, goal setting, stimulus control, problem solving, and relapse prevention. Each session will also include a short education component on healthy eating to improve participants' adherence to the updated Canada's Food Guide. Participants will have access to web-based exercise training sessions. Intervention sessions will be delivered online.
Study NCT04660968 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dyadic nutrition counselling intervention
Description: The couples-based education nutrition intervention will provide extensive information on healthy eating. However, it will not include any behavioural change principles. Topics will be based on Dietitians of Canada's Practice-based Evidence in Nutrition (PEN) discussions in the database that focus on healthy eating for older adults. The topics covered will include increasing fruits and vegetables, hidden (empty) calories, how to read food labels, portion control, reducing salt and saturated fat, plant-based proteins, and eating for healthy bones. Participants in this group will also be told to increase their levels of physical activity to 150 minutes of moderate to vigorous physical activity per week, as per the Canadian Guidelines. Participants will have access to web-based exercise training sessions. However, physical activity will not be discussed explicitly during the intervention. Intervention sessions will be delivered online.
Study NCT00542945 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICD
Description: Implantation of an ICD
Study NCT00542945 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medical treatment
Description: ACE-inhibitors or ARB Beta-blocker Optional aldosterone antagonist
Study NCT03244592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: 200 mg/day
Study NCT03074448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Picosulfate
Description: Sodium Picosulfate solution (Picoprep)
Study NCT02151500 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress and Health Interview
Description: A stress and health interview which aims to help patients: a) disclose their stressful experiences and emotional conflicts, which might be contributing to their symptoms; b) learn about associations between their stress and physical symptoms; and c) learn about the potential value of experiencing and expressing their emotions related to these stressful situations.
Study NCT00573326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: 200 mg p.o. once a day for 6 months
Study NCT04056130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBL697
Description: Part A: 1 day 460mg/day of KBL697 or placebo~Route of Administration: Oral
Study NCT04056130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBL697
Description: Part A: 1 day 4,600mg/day of KBL697~Route of Administration: Oral
Study NCT04056130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBL697
Description: Part B: 14 days~Cohort MAD1:~460mg/day of KBL697~Route of Administration: Oral
Study NCT04056130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBL697
Description: Part B: 14 days~Cohort MAD2:~4,600mg/day of KBL697~Route of Administration: Oral
Study NCT03671759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Start: On Caffeine
Description: In this two-day block, participants will be instructed to consume caffeine for one day and avoid caffeine the next day.
Study NCT03671759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Start: Off Caffeine
Description: In this two-day block, participants will be instructed to avoid caffeine for one day and consume caffeine the next day.
Study NCT03059563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline is an FDA-approved medication to facilitate smoking cessation. it is also a promising candidate to enhance dopamine signaling by upregulating dopamine D2/D3 (type 2) receptors in the striatum and improve cognitive function.
Study NCT03059563 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo containing no active ingredients will be used as a control to assess the effects of varenicline on dopamine D2/D3 receptor availability and cognitive function.
Study NCT03321240 — intervention group
Intervention type: PROCEDURE
Intervention: visual and quantitative SEEG signal analysis
Description: signal SEEG analysis
Study NCT03321240 — intervention group
Intervention type: PROCEDURE
Intervention: Resective epilepsy surgery procedure
Description: Surgical removal of the epileptogenic brain area
Study NCT01505491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: 40mg adalimumab single s.c. injection
Study NCT01505491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI695501
Description: BI 695501 single s.c injection
Study NCT02230124 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRE
Study NCT00227279 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALK Grass tablet
Description: Tablets, 75,000 SQ-T or matching placebo. Daily administration for 3 years
Study NCT00227279 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ALK Grass tablet
Description: Tablets, 75,000 SQ-T or matching placebo. Daily administration for 3 years